Ipilimumab Mechanism and Clinical Applications

Mechanism of Action

CTLA-4 is a negative regulator of T-cell activity that normally functions as an immune checkpoint, limiting immune responses, and ipilimumab blocks its interaction with its ligands, preventing inhibitory signaling cascades that suppress T-cell activation, according to the National Comprehensive Cancer Network 1, 2
The blockade of CTLA-4 by ipilimumab primarily interferes with the feedback mechanism at the interface between T cells and antigen-presenting dendritic cells, as stated by the National Comprehensive Cancer Network 2

The enhanced immune response allowed by ipilimumab enables the body's natural immune surveillance mechanisms to better identify and destroy malignant cells, as noted by the National Comprehensive Cancer Network 1
Ipilimumab's mechanism differs from anti-PD-1 inhibitors, which primarily interfere with the feedback mechanism at the interface of T cells and tumor cells, according to the National Comprehensive Cancer Network 2

Ipilimumab was the first immune checkpoint inhibitor approved by the FDA in 2011 for treatment of metastatic melanoma, as reported in the Journal for ImmunoTherapy of Cancer 3
It has demonstrated significant improvement in overall survival in patients with unresectable stage III or stage IV melanoma, with a durable long-term survival in approximately 20% of patients with advanced disease, as stated by the National Comprehensive Cancer Network 1, 2
The FDA-recommended dose for metastatic disease is 3 mg/kg, while the adjuvant treatment dose is higher at 10 mg/kg, according to the National Comprehensive Cancer Network 4
Higher doses (10 mg/kg) are associated with improved overall survival but also significantly higher rates of treatment-related adverse events compared to the 3 mg/kg dose, as noted by the National Comprehensive Cancer Network 1
Immune-related adverse events (irAEs) are common with ipilimumab due to its mechanism of action, affecting up to 90% of patients with any-grade irAEs, as reported in the Journal for ImmunoTherapy of Cancer 5